Pirtobrutinib vs zanubrutinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Mantle Cell Lymphoma

Shared mechanism: BTK · full Mantle Cell Lymphoma pipeline

Pirtobrutinib

Marketed by Eli Lilly

Approved in Mantle Cell Lymphomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06522386 (registry estimate)

No aligned efficacy figure on record for this race.

zanubrutinib · Brukinsa

Marketed by BeOne Medicines

Approved in Mantle Cell Lymphomasmall molecule
Weak signal

NCT03206970 · Phase 2 · completed

All 86 participants received zanubrutinib, with no randomization, no blinding and no comparison group. The response rate cleared a fixed benchmark of 40%, but without a control group the study cannot show how much of the result is due to the drug.

Next expected readout: December 2026 · NCT06504199 (registry estimate)

Reported efficacy

Progression-free survival (PFS) determined by independent central review (Up to approximately 7 years): Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01). (met)

Result source: NCT04002297

Results for Mantle Cell Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pirtobrutinib: no structured comparison results are available for Mantle Cell Lymphoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

zanubrutinib
Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results). NCT03206970 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result
Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01). NCT04002297 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Chronic Lymphocytic Leukemia

Shared mechanism: BTK · full Chronic Lymphocytic Leukemia pipeline

Pirtobrutinib

Marketed by Eli Lilly

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT04666038 · Phase 3 · active, not recruiting

Patients were randomised 1:1 against active standard options and the primary endpoint, independently assessed progression-free survival, was met (hazard ratio 0.536, p=0.0002) in 238 patients. The trial was open-label, so patients and clinicians knew the assigned treatment, and the comparator was a mix of two regimens with crossover allowed after progression.

Next expected readout: December 2026 · NCT06466122 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Arm A - Pirtobrutinib 13.96 Months (95% CI 11.24 to 16.56) | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab 8.74 Months (95% CI 8.08 to 10.38) (met)

Result source: NCT04666038

zanubrutinib · Brukinsa

Marketed by BeOne Medicines

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT03734016 · Phase 3 · completed

The trial was large and randomized, with 327 participants receiving zanubrutinib and 325 receiving active-comparator ibrutinib, but neither participants nor investigators were blinded. The primary clinical response endpoint was met, with statistically significant superiority for zanubrutinib by both investigator and independent review; the open-label design supports moderate rather than strong evidence.

Next expected readout: December 2026 · NCT05873712 (registry estimate)

Reported efficacy

Overall Response Rate (ORR) Assessed by the Investigator (From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).); ORR Assessed by the Independent Review Committee (IRC) (From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).): Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). (met)

Result source: NCT03734016

Results for Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pirtobrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

zanubrutinib
Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). NCT03734016 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pirtobrutinib's landscape · zanubrutinib's landscape